2024
Shared genetics of ADHD, cannabis use disorder and cannabis use and prediction of cannabis use disorder in ADHD
Nielsen T, Duan J, Levey D, Walters G, Johnson E, Thorgeirsson T, Werge T, Mortensen P, Stefansson H, Stefansson K, Hougaard D, Agrawal A, Gelernter J, Grove J, Børglum A, Demontis D. Shared genetics of ADHD, cannabis use disorder and cannabis use and prediction of cannabis use disorder in ADHD. Nature Mental Health 2024, 2: 1071-1083. DOI: 10.1038/s44220-024-00277-3.Peer-Reviewed Original ResearchAttention-deficit hyperactivity disorderCannabis use disorderCannabis useUse disorderPolygenic scoresComorbid cannabis use disorderStudies of attention-deficit hyperactivity disorderCross-disorder genome-wide association studySubstance-use disordersIncreased polygenic scoresBrain developmental stagesRisk genesCross-disorderConditions co-occurringPsychiatric disordersHyperactivity disorderGenome-wide significant lociSubstance useRare deleterious variantsCannabisDisordersSignificant lociDeleterious variantsSex-specific differencesBrain
2023
Genome-wide association study of antisocial personality disorder diagnostic criteria provides evidence for shared risk factors across disorders
Li W, Zhou H, Thygesen J, Heydtmann M, Smith I, Degenhardt F, Nöthen M, Morgan M, Kranzler H, Gelernter J, Bass N, McQuillin A. Genome-wide association study of antisocial personality disorder diagnostic criteria provides evidence for shared risk factors across disorders. Psychiatric Genetics 2023, 33: 233-242. PMID: 37756443, PMCID: PMC10635348, DOI: 10.1097/ypg.0000000000000352.Peer-Reviewed Original ResearchConceptsAntisocial personality disorderAttention deficit hyperactivity disorderSubstance use disordersPosttraumatic stress disorderGenome-wide association studiesDeficit hyperactivity disorderDisorder diagnostic criteriaRisk factorsFrontal cortexDiagnostic criteriaUse disordersRisk score analysisAnterior cingulateAlcohol-dependent participantsPsychiatric conditionsSignificant associationBrain regionsPersonality disorder diagnostic criteriaStress disorderAnxiety disordersASPD criteriaHyperactivity disorderPolygenic risk score analysisPersonality disorderScore analysis
2018
Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder
Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, Baldursson G, Belliveau R, Bybjerg-Grauholm J, Bækvad-Hansen M, Cerrato F, Chambert K, Churchhouse C, Dumont A, Eriksson N, Gandal M, Goldstein JI, Grasby KL, Grove J, Gudmundsson OO, Hansen CS, Hauberg ME, Hollegaard MV, Howrigan DP, Huang H, Maller JB, Martin AR, Martin NG, Moran J, Pallesen J, Palmer DS, Pedersen CB, Pedersen MG, Poterba T, Poulsen JB, Ripke S, Robinson EB, Satterstrom FK, Stefansson H, Stevens C, Turley P, Walters GB, Won H, Wright MJ, Andreassen O, Asherson P, Burton C, Boomsma D, Cormand B, Dalsgaard S, Franke B, Gelernter J, Geschwind D, Hakonarson H, Haavik J, Kranzler H, Kuntsi J, Langley K, Lesch K, Middeldorp C, Reif A, Rohde L, Roussos P, Schachar R, Sklar P, Sonuga-Barke E, Sullivan P, Thapar A, Tung J, Waldman I, Medland S, Stefansson K, Nordentoft M, Hougaard D, Werge T, Mors O, Mortensen P, Daly M, Faraone S, Børglum A, Neale B. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics 2018, 51: 63-75. PMID: 30478444, PMCID: PMC6481311, DOI: 10.1038/s41588-018-0269-7.Peer-Reviewed Original ResearchConceptsGenome-wide significant risk lociFunction intolerant genesGenome-wide associationSignificant risk lociGenome-wide significanceAttention-deficit/hyperactivity disorderCommon genetic variantsGenomic regionsIntolerant genesIndependent lociRegulatory marksHeritable traitRisk lociDeficit/hyperactivity disorderGenetic variantsGenetic overlapStudy-specific differencesLociHyperactivity disorderImportant new informationUnderlying biologyChildhood behavioral disordersVariantsStrong concordanceGWAS
2012
GABRA2 Genotype, Impulsivity, and Body Mass
Bauer LO, Yang B, Houston RJ, Kranzler HR, Gelernter J. GABRA2 Genotype, Impulsivity, and Body Mass. American Journal On Addictions 2012, 21: 404-410. PMID: 22882390, PMCID: PMC3773931, DOI: 10.1111/j.1521-0391.2012.00252.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttention Deficit Disorder with HyperactivityBody Mass IndexCase-Control StudiesConnecticutFemaleGenotypeHumansImpulsive BehaviorMaleMiddle AgedPolymorphism, Single NucleotidePsychiatric Status Rating ScalesReceptors, GABA-ASex FactorsSubstance Abuse Treatment CentersSubstance-Related DisordersConceptsBody mass indexElevated body mass indexAssociation of BMIGABRA2 genotypeSubstance dependenceAttention-deficit/hyperactivity disorderHigh-calorie foodsPrevious pregnancyMass indexElectroencephalographic featuresRisk factorsChildhood symptomsScale scoreDrug abstinenceCalorie foodsHyperactivity disorderGenetic findingsWomenLonger durationBarratt Impulsiveness ScalePsychological indicatorsGABRA2 variantsSex differencesSecond analysisBody mass
2008
Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disorders
Arias AJ, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, Kranzler HR. Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disorders. Addictive Behaviors 2008, 33: 1199-1207. PMID: 18558465, PMCID: PMC2532519, DOI: 10.1016/j.addbeh.2008.05.003.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderFirst substance useOpioid dependenceLifetime diagnosisSubstance useCo-occurring attention-deficit hyperactivity disorderSubstance dependence disordersDrug-dependent subjectsSemi-Structured AssessmentDeficit hyperactivity disorderClinical courseMore hospitalizationsSevere coursePsychiatric comorbiditySD diagnosisDependence disordersPsychiatric disordersADHD prevalencePsychiatric diagnosisDrug dependenceMore SDsSubstance dependenceConduct disorderDiagnosisHyperactivity disorder
2001
The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans
Martinez D, Gelernter J, Abi-Dargham A, van Dyck C, Kegeles L, Innis R, Laruelle M. The Variable Number of Tandem Repeats Polymorphism of the Dopamine Transporter Gene Is Not Associated with Significant Change in Dopamine Transporter Phenotype in Humans. Neuropsychopharmacology 2001, 24: 553-560. PMID: 11282255, DOI: 10.1016/s0893-133x(00)00216-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmphetamineAttention Deficit Disorder with HyperactivityBenzamidesCarrier ProteinsCocaineCocaine-Related DisordersDopamineDopamine AntagonistsDopamine Plasma Membrane Transport ProteinsGenotypeHumansIodine RadioisotopesMembrane GlycoproteinsMembrane Transport ProteinsMinisatellite RepeatsNeostriatumNerve Tissue ProteinsPhenotypePolymorphism, GeneticPsychotic DisordersPyrrolidinesRadiopharmaceuticalsSchizophreniaTomography, Emission-Computed, Single-PhotonConceptsAmphetamine-induced dopamine releaseDopamine releaseDAT expressionDopamine transporterDifferent patient populationsAttention deficit hyperactivity disorderDeficit hyperactivity disorderNeurochemical phenotypePatient populationHealthy controlsDAT densityComputerized emission tomographyDopamine transmissionClinical phenotypeDiagnostic groupsSignificant associationEmission tomographyCocaine-induced paranoiaHyperactivity disorderTandem repeat polymorphismVNTR polymorphismDopamine transporter geneRepeat polymorphismTotal sample